DiVision Medical Raises Nearly RMB 100 Million in Series A Funding to Accelerate Clinical Applications and Commercialization of Microsurgical Robots
Dessight Biomedical
Developer of Microsurgical Robotics Platform
WinX Capital
Investment Institutions in the Greater Health Field
Panlin Capital
Technology Innovation-Oriented Early-Stage and Mid-Stage Venture Capital Institutions
Kinghall Ventures
Healthcare Investment Institutions
VCBeat has learned thatHangzhou Dessight Biomedical Co. Ltd. has recently completed a funding round of nearly RMB 100 millionAround of financing, led by Panlin Capital, with participation from Shangcheng Capital and Kinghall Ventures,Hangzhou Sci-Tech Innovation Group（Disruptive Technology Commercialization Fund) co-investment, with WinX Capital serving as the exclusive financial advisor.This round of funding will be used to accelerate the registration and clinical trials of the general microsurgical robot, as well as the commercial promotion of the ophthalmic surgical robot product, further consolidating the technological advantages of Dessight Biomedical's core products and enhancing the ecosystem of its robotic microsurgery product series.
Dessight Biomedical was established in July 2021. It is a National High-Tech Enterprise, a Zhejiang Province “Specialized, Refined, Differential, and Innovative” SME, and a co-constructor of a Key Provincial Laboratory in Zhejiang. The founding team hails from top-tier universities and enterprises, including Zhejiang University, the Technical University of Munich, and Fortune 500 German pharmaceutical companies. To date, Dessight Biomedical has filed for and been granted dozens of invention patents in China and the United States, and has won multiple awards at prestigious domestic and international competitions.
In the field of R&D and commercialization of microsurgical robots, Dessight Biomedical has consistently maintained a leading edge in technology and product development. Among them,Dessight Biomedical's ophthalmic surgical robot has completed China's first registered clinical trial at several leading Grade 3A hospitals., the product has successfully passed the review by the Center for Medical Device Technical Evaluation of the National Medical Products Administration (NMPA),Officially entered the "Green Channel" for Special Review of Innovative Medical Devices, becoming the first ophthalmic surgical robot in China to enter this channel, poised to fill the gap in the commercialization of ophthalmic surgical robots in China, and provide more precise and safe treatment options for over 40 million patients with fundus diseases in the country.
Dessight Biomedical's Ophthalmic Surgical Robot Featured on CCTV
In addition, the general-purpose microsurgical robot developed by Dessight Biomedical,Yu2025Year1The world's first robot-assisted supermicrosurgery for deep cervical lymphatics was successfully completed in May-Venous Anastomosis (LVA) treatment of Alzheimer's disease, and the first robot-assisted case of lymphedema in ChinaLVAReconstruction SurgeryLeveraging Dessight Biomedical’s independently developed micron-level motion control, micro-wristed instruments, and flexible grasping technology, this microsurgical robot can perform lymphaticovenous anastomosis with a precision of up to 0.1 mm, overcoming the therapeutic limitations imposed by physiological tremors in traditional surgery and significantly enhancing surgical safety and accuracy.
Currently, Dessight’s products have served dozens of hospitals, delivering innovative treatment enhancements to hundreds of patients. They have transformed delicate therapeutic procedures that were difficult to perform under traditional microscopes into safe, controllable, robot-assisted precision operations, truly achieving a substantive and effective integration of disruptive technology with innovative products that address critical clinical pain points.
People's Daily Reports on Dessight Microsurgical Robot Performing 0.2mm Lymphaticovenular Anastomosis at Zhejiang Provincial People's Hospital
Dr. Cui Di, Founder of Dessight Biomedical, stated: Microsurgery is a category of highly complex and delicate procedures that surpass the physiological limits of manual dexterity. There is a critical need for microsurgical robots, which offer distinct advantages in enhancing operational stability, improving surgical precision and degrees of freedom, accessing deep tissues that are difficult to reach with traditional microsurgery, and alleviating surgeon fatigue during prolonged procedures. The microsurgical robots and related products developed by Dessight Biomedical have been deployed in dozens of leading hospitals, serving hundreds of patients.
We extend our sincere gratitude to Panlin Capital, the leaders of Hangzhou’s Shangcheng District, Shangcheng Capital, Kinghall Ventures, Hangzhou Sci-Tech Innovation Group, and other new and existing investors for their trust and support. Dessight Biomedical will continue to expand the application of robotic micromanipulation technology in ophthalmology and microsurgery, committed to providing high-precision, user-friendly, perceptible, and digital solutions for clinical surgeries and life sciences research. With the strengthened support from our shareholders in this new round, we are confident that Dessight’s products will play an even more significant role in safeguarding human health and well-being, benefiting doctors and patients worldwide.
Zhou Mingchuan, Researcher at Zhejiang University and Vice President of Dessight Biomedical, stated:The past three decades have defined the Internet era, while the next thirty years will usher in the age of intelligent robotics. Robots will not only assist humanity in reaching for the vast stars but also enable us to connect with the microscopic world, which is impossible to observe with the naked eye or manipulate by hand. Robotic micromanipulation facilitates precise dexterous operations at the microscale, holding significant application value in healthcare, agriculture, and industry. Dessight Biomedical has entered and deeply cultivated the field of robotic micromanipulation, effectively helping microsurgical surgeons transcend physiological limits. By providing more stable, safe, precise, quantifiable, and visualized operational capabilities, it significantly enhances operators’ control over delicate tissue manipulation.
Xue Mengjun, Managing Partner at Panlin Capital, stated:Ultra-microsurgical robots can transcend the physical limitations of manual dexterity, addressing critical pain points in surgical procedures. Characterized by significant clinical value, high technical barriers, robust market demand, and an early stage of industrial development, this sector represents the next blue ocean market in the field of surgical robotics. The team at Dessight Biomedical has maintained long-term communication with clinicians to develop ophthalmic and microsurgical robotic systems that best meet clinical needs. By establishing a core technology platform based on independent innovation, the company is well-positioned to drive continuous product iteration. This investment marks another strategic move by Panlin Capital in the innovative medical device sector, specifically targeting R&D-driven enterprises. Panlin Capital aims to support Dessight Biomedical throughout its growth journey, helping it evolve into a globally leading technology platform enterprise for ultra-microsurgical robotics.
We remain bullish on and fully support Dessight Biomedical’s groundbreaking contributions to the field of super-microsurgical robotics. Its core technology, featuring a globally leading motion precision of 3 micrometers, has redefined the performance benchmark for surgical robots. Its ophthalmic surgical robot became the first product in China to enter the National Medical Products Administration (NMPA) “Green Channel” for Innovative Medical Devices, poised to fill the gap in the commercialization of ophthalmic surgical robots in the domestic market. Furthermore, its microsurgical robotic system is expected to deliver significant application value in neurosurgery, vascular surgery, plastic surgery, otolaryngology, and other specialties. We look forward to Dessight Biomedical leveraging Shangcheng District in Hangzhou as an innovation hub to develop intelligent microscopic operation platforms that surpass human limits, thereby providing patients with more efficient and safer diagnostic and therapeutic solutions, and creating substantial clinical value and social benefits.
Wang Xiaoping, Deputy Director of the Qiantang Smart City Management CommitteeFrom the Perspective of Industry-Capital IntegrationIndicates:Behind the industry’s shift toward “new” frontiers, the support of industrial funds is indispensable. As a leading enterprise in the field of ophthalmic microsurgical assistance robots within Qiantang Smart City, Dessight Biomedical has always received significant attention from the park. This joint investment in Dessight Biomedical, undertaken together with Shangcheng Capital, will promote the integration of industry and capital, deepen the empowering role of the district’s guidance fund in supporting the real economy within the district, effectively help the company achieve better development, secure competitive advantages, and widen its lead over industry peers. Qiantang Smart City sincerely wishes Dessight Biomedical continued growth and innovation, making breakthrough contributions to the field of ultra-microsurgical robots.
Hao Bixi, Managing Partner of Kinghall Ventures, stated:Dessight Biomedical has accumulated years of expertise in the field of microsurgery. The company leverages its foundational technologies to address clinical pain points, assisting surgeons in performing highly challenging super-microsurgical procedures, thereby offering broad application prospects. Kinghall Ventures has long been deeply engaged in the healthcare industry. We are highly optimistic about the Dessight team’s efficient execution capabilities and growth potential, and we look forward to the company emerging as a leading enterprise in this sector, both in China and globally.
A representative of Hangzhou Science and Technology Innovation Group stated:We are closely monitoring and remain optimistic about the growth potential of the microsurgical robotics sector. Dessight Biomedical has demonstrated disruptive technological prowess and rapid product commercialization capabilities in this field. Its ophthalmic surgical robot has been admitted to the National Medical Products Administration’s “Green Channel” for innovative medical devices, while its microsurgical robot successfully completed the first robot-assisted lymphaticovenous anastomosis (LVA) procedure for the treatment of Alzheimer’s disease, preliminarily validating its technical value and clinical potential. Hangzhou Sci-Tech Innovation will support Dessight in accelerating product deployment, filling domestic gaps, and benefiting a broad patient population.
Li Lincan, Vice President of WinX Capital, stated:WinX Capital is honored to have once again served as the exclusive financial advisor for Dessight Biomedical’s financing round. Over the years, we have witnessed the rapid development of Dessight’s supermicrosurgery platform, which has evolved from its initial focus on ophthalmic surgical robots to encompass supermicrosurgical surgical robots, propelling the company to a leading position in this specialized sector. We congratulate Dessight Biomedical on completing its latest round of financing and on performing the world’s first supermicrosurgical robot-assisted deep cervical lymphaticovenous anastomosis (LVA) procedure for the treatment of Alzheimer’s disease. We look forward to the imminent market launch of Dessight Biomedical’s ophthalmic and supermicrosurgical robotic systems, which will facilitate precise clinical interventions and leverage technology to benefit more patients.
About Panlin Capital
Panlin Capital is a venture capital firm with both professionalism and influence in the healthcare and technology sectors.
Panlin Capital, established in 2010, adheres to the investment theme of “Technology Creates the Future, Innovation Leads Upgrading.” Focusing on the healthcare and technology sectors, it identifies angel to Series A projects, dedicated to “finding entrepreneurs among scientists and fostering innovators among entrepreneurs.”
In the healthcare sector, Panlin Capital targets innovative drug developers and innovative medical device manufacturers focused on the prevention, diagnosis, and treatment of major diseases with unmet clinical needs, while also seeking derivative investment opportunities in life sciences and biotechnology. In the technology sector, it invests in B2B enterprises (enterprise services and data-intelligent equipment) that address corporate demands for cost reduction, efficiency enhancement, and quality improvement, as well as in hard-tech companies (equipment and key components) that ensure autonomous control over critical technologies.
About Shangcheng Capital
Shangcheng Capital serves as the entrusted manager of Hangzhou Shangcheng District’s development fund, which has a total scale of RMB 10 billion (comprising RMB 7 billion in industry-focused funds and RMB 3 billion in venture capital funds). The fund strategically targets advantageous future industry sectors, including artificial intelligence, intelligent Internet of Things (AIoT), advanced manufacturing, and the digital economy. Furthermore, Shangcheng Capital has collaborated with industry leaders, prominent venture capital firms, and provincial and municipal state-owned enterprises to establish 16 sub-funds, with a combined total scale approaching RMB 10 billion. Shangcheng Capital will continue to leverage its “sub-fund + direct investment” model to encourage diverse capital participation in the investment and cultivation of innovative industries within Shangcheng District. It is fully committed to facilitating the establishment of corporate headquarters, R&D centers, and future industry projects, thereby fostering a virtuous cycle between industrial investment and capital operations.
About Kinghall Ventures
Kinghall Ventures, established in 2017, is a professional investment institution focused on the healthcare sector. Based in the Greater Bay Area with a nationwide reach, its fund manager has attracted market-oriented capital and government guidance funds from across China. It has made deep strategic investments in typical healthcare segments, including the in vitro diagnostics (IVD) industry chain, life science research tools, innovative medical devices, consumer healthcare and medical services, and novel drug development. By building a sustainable boutique healthcare fund and an industrial ecosystem, Kinghall Ventures aims to cultivate healthcare enterprises with international competitiveness.
About Hangzhou Sci-Tech Innovation Group
Hangzhou Sci-Tech Innovation Group is a wholly-owned subsidiary of Hangzhou State-owned Capital Investment and Operation Co., Ltd. Committed to discovering and cultivating innovative value, the Group manages the “Hangzhou Sci-Tech Innovation Fund,” with an operational scale of RMB 100 billion. It has invested in over 2,400 enterprises, cumulatively nurtured 120 listed companies, and incubated high-tech, high-growth enterprises such as Unitree Robotics, BrainCo, and DeepRobotics, known as the “Six Little Dragons.” The Hangzhou Gaotou Disruptive Technology Achievement Transformation Fund, initiated by Hangzhou Sci-Tech Innovation Group, aims to identify and invest in a batch of forward-looking, leading, and disruptive technological achievements. By providing early-stage nurturing and ongoing support, the fund facilitates the development of new quality productive forces.
About WinX Capital
WinX Capital is a leading investment bank in China’s healthcare industry, headquartered in Beijing and Shanghai, with offices in Shenzhen and Hangzhou. It has received numerous accolades, including Qimingpian’s “No. 1 Financial Advisor in Healthcare for 2024,” First New Voice’s “No. 1 Financial Advisory Firm in Healthcare (2022–2024),” and VCBeat’s “Annual Healthcare Financial Advisor among the Future Healthcare 100 (2022–2024).”